Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anfibatide
- Development stage
- Phase 2
- Lead developer
- Lee's Pharmaceutical
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Anfibatide is a novel antiplatelet agent derived from the venom of the snake *Agkistrodon acutus*. It functions as a specific antagonist of the platelet glycoprotein Ib (GPIb) receptor, specifically the GPIb-IX-V complex. By blocking the binding site for von Willebrand factor (vWF) on the GPIb alpha subunit, anfibatide inhibits platelet adhesion and aggregation, particularly under high-shear stress conditions typical of arterial thrombosis. Developed by Lee's Pharmaceutical, the drug is primarily being evaluated for the treatment of acquired thrombotic thrombocytopenic purpura (TTP) and acute coronary syndromes, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). Clinical studies suggest that anfibatide offers potent anti-thrombotic effects with a lower risk of bleeding compared to traditional antiplatelet therapies and exhibits rapid reversibility.
- Other names
- Antiplatelet ThrombolysinAntiplatelet Thrombolysin for Injection
02
Targets
GP1BA (Platelet glycoprotein ib alpha chain)
Beyond the preview
Go deeper on anfibatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anfibatide.